PREVIOUS ISSUE NEXT ISSUE
January 2017 DT0117_001Cover.jpg
Reflections on legacies, lessons and inspirationsThe New Year is a time during which most of us celebrate the idea of fresh starts. It’s also a time of reflection. In the spirit of this New Year, Dermatology Times asked several top dermatologists to ponder their legacies.
Can I be sued for off-label use?If a patient’s procedure uses a device that is not FDA-approved, or is FDA-approved for another purpose, or is experimental, must the patient be so advised by the physician to provide appropriate informed consent? Courts have wrestled with this matter in a number of legal opinions.
If I ruled the (dermatology) worldDr. Norman Levine muses on an alternate universe in which he makes the rules for anything related to the dermatology specialty. After reading, he notes many may be relieved that he will never rule the (dermatology) world. But are changes necessary? You tell us.
The role of neuroinflammation in rosaceaNeuroinflammation has recently been recognized as one of the possible factors leading to the development of rosacea. As such, future therapies targeting this pathway could prove effective in rosacea treatment.
Study offers new insight into pediatric eczemaResearchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease.
Advances in pediatric inflammatory skin diseaseExciting research is likely to change treatment for children. Dr. Eichenfield discusses advancements in treating this population.
Pearls to optimize safety, success with biologicsOne dermatologist describes his considerations for choosing a biologic to treat a patient with moderate-to-severe psoriasis, baseline assessments, and follow-up approach.
Acne responds to energy-based therapiesEnergy-based treatments can be used on their own or in conjunction with medical treatments to address chronic dermatological conditions like melasma, acne, and vitiligo.
Most puzzling diagnoses of 2016In 2016, Dermatology Times, in partnership with VisualDx, quizzed you on a number of different skin disease diagnoses. From morphea to poikiloderma of civatte to livedo reticularis, we’ve shown cases that have stumped the most experienced dermatologists. Here are the three most-puzzling quizzes of 2016.
First-ever U.S. psoriasis treatment goalsThe National Psoriasis Foundation has recently published psoriasis treatment goals, which will help physicians and patients discuss treatment options and set expectations for outcomes.
Factors in rosacea pathogenesis clearerKeeping abreast of findings regarding the immunological, neurological and vascular roots of rosacea helps dermatologists target treatments accordingly, experts say.
Fractioned laser benefits for skin resurfacingFractioned laser systems for skin resurfacing can be separated into four categories and there are benefits to each type depending on the type of patient being treated.
World-wide skin cancer epidemiologyThe incidence of melanoma appears to be on the rise except for that observed in the younger population, underscoring a positive trend and hope for the fight against skin cancer.
AMA drives push for drug pricing transparency with grassroots campaignThe AMA has emphasized a need for drug pricing transparency by encouraging patients to share their stories on its TruthinRx.org website.
How the Trump presidency may impact dermatologyDermatology’s leaders share perspectives on how the new Administration may impact medicine.
What should dermatologists do when a merger beckons?Many dermatologists are approached by parties interested in acquiring a practice. Knowing ahead of time what questions you should ask—and how to answer their questions—can turn a simple inquiry by them into a wealth of information for you.
PREVIOUS ISSUE NEXT ISSUE